Susquehanna Fundamental Investments LLC Grows Stake in Sutro Biopharma, Inc. (NASDAQ:STRO)

Susquehanna Fundamental Investments LLC boosted its position in shares of Sutro Biopharma, Inc. (NASDAQ:STRO) by 78.2% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 225,367 shares of the company’s stock after purchasing an additional 98,908 shares during the quarter. Susquehanna Fundamental Investments LLC owned approximately 0.28% of Sutro Biopharma worth $660,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. ProShare Advisors LLC raised its stake in shares of Sutro Biopharma by 49.1% during the 2nd quarter. ProShare Advisors LLC now owns 16,316 shares of the company’s stock worth $48,000 after buying an additional 5,373 shares during the last quarter. Lazard Asset Management LLC acquired a new position in Sutro Biopharma during the first quarter worth about $92,000. The Manufacturers Life Insurance Company lifted its holdings in shares of Sutro Biopharma by 27.4% in the second quarter. The Manufacturers Life Insurance Company now owns 32,943 shares of the company’s stock valued at $97,000 after purchasing an additional 7,082 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in shares of Sutro Biopharma by 24.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 18,027 shares of the company’s stock valued at $102,000 after purchasing an additional 3,578 shares during the last quarter. Finally, Hsbc Holdings PLC grew its position in shares of Sutro Biopharma by 9.7% in the second quarter. Hsbc Holdings PLC now owns 60,858 shares of the company’s stock valued at $173,000 after purchasing an additional 5,404 shares during the last quarter. Institutional investors and hedge funds own 96.99% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently issued reports on the company. JMP Securities restated a “market outperform” rating and set a $17.00 price objective on shares of Sutro Biopharma in a research report on Monday, September 16th. HC Wainwright restated a “buy” rating and issued a $12.00 price objective on shares of Sutro Biopharma in a research report on Monday, September 16th. Finally, Truist Financial decreased their price objective on Sutro Biopharma from $18.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, August 16th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $12.13.

Sutro Biopharma Trading Up 0.3 %

Sutro Biopharma stock opened at $3.51 on Thursday. The stock has a fifty day moving average price of $4.03 and a 200 day moving average price of $3.94. Sutro Biopharma, Inc. has a 52 week low of $2.01 and a 52 week high of $6.13. The firm has a market capitalization of $287.10 million, a P/E ratio of -1.87 and a beta of 1.18.

Sutro Biopharma (NASDAQ:STRO) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.59) EPS for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.20. Sutro Biopharma had a negative net margin of 73.48% and a negative return on equity of 102.06%. The company had revenue of $25.71 million during the quarter, compared to the consensus estimate of $26.28 million. As a group, equities analysts predict that Sutro Biopharma, Inc. will post -2.96 EPS for the current year.

Sutro Biopharma Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.